TYVPANASL

This nine-residue peptide, TYVPANASL, is a HER2/neu-derived MHC class I epitope for CD8+ T cells. It serves as a critical component for constructing J-LEAPS immunotherapeutic vaccines, enabling research in cancer immunology and vaccine development for both in vitro T cell assays and in vivo preclinical studies.